HomeCompareBMY vs OWL

BMY vs OWL: Dividend Comparison 2026

BMY yields 4.17% · OWL yields 9.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OWL wins by $414352.62M in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
OWL
OWL
● Live price
9.92%
Share price
$9.07
Annual div
$0.90
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$414352.74M
Annual income
$406,483,270,930.14
Full OWL calculator →

Portfolio growth — BMY vs OWL

📍 OWL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYOWL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + OWL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
OWL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
OWL
Annual income on $10K today (after 15% tax)
$843.44/yr
After 10yr DRIP, annual income (after tax)
$345,510,780,290.62/yr
At 15% tax rate, OWL beats the other by $345,510,746,440.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + OWL for your $10,000?

BMY: 50%OWL: 50%
100% OWL50/50100% BMY
Portfolio after 10yr
$207176.43M
Annual income
$203,241,655,376.90/yr
Blended yield
98.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
OWL
Analyst Ratings
1
Strong
11
Buy
7
Hold
Consensus: Buy
Price Target
$16.33
+80.0% upside vs current
Range: $10.00 — $27.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
OWL buys
0
No recent congressional trades found for BMY or OWL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYOWL
Forward yield4.17%9.92%
Annual dividend / share$2.49$0.90
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%100%
Portfolio after 10y$120.5K$414352.74M
Annual income after 10y$39,823.66$406,483,270,930.14
Total dividends collected$91.0K$413819.97M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$16.33

Year-by-year: BMY vs OWL ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrOWL PortfolioOWL Income/yrGap
1← crossover$11,271$571.12$12,685$1,984.56$1.4KOWL
2$12,884$824.20$18,278$4,705.30$5.4KOWL
3$14,993$1,206.32$32,230$12,673.05$17.2KOWL
4$17,839$1,797.27$76,257$41,770.33$58.4KOWL
5$21,826$2,738.11$266,321$184,726.08$244.5KOWL
6$27,643$4,289.31$1,490,836$1,205,872.37$1.46MOWL
7$36,534$6,955.64$14,212,664$12,617,469.92$14.18MOWL
8$50,861$11,770.13$240,042,713$224,835,162.78$239.99MOWL
9$75,402$20,980.23$7,354,641,310$7,097,795,606.72$7354.57MOWL
10$120,504$39,823.66$414,352,737,132$406,483,270,930.14$414352.62MOWL

BMY vs OWL: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

OWLStock

Blue Owl Capital Inc. operates as an asset manager. It offers permanent capital base solutions that enables it to offer a holistic platform to middle market companies, large alternative asset managers, and corporate real estate owners and tenants. The company provides direct lending products that offer private credit products comprising diversified, technology, first lien, and opportunistic lending to middle-market companies; GP capital solutions products, which offers capital solutions, including GP minority equity investments, GP debt financing, and professional sports minority investments to large private capital managers; and real estate products that focuses on structuring sale-leaseback transactions, which includes triple net leases. It offers its solutions through permanent capital vehicles, as well as long-dated private funds. The company is headquartered in New York, New York.

Full OWL Calculator →
📬

Get this BMY vs OWL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.